Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and Performance Validation of a Comprehensive Liquid Biopsy Genotyping Panel for Pan-cancer Analysis.

Annals of laboratory medicine - 1 Mar 2026

Lim Seoyoung, Lee Kwang Seob, Won Dongju, Seo Sung Hyun, Lee Seung-Tae, Choi Jong Rak, Seo Jieun, Shin Saeam

Abstract excerpt

Background: Precision oncology is advancing, increasing the demand for comprehensive, non-invasive genomic profiling tools. Liquid biopsy using circulating tumor DNA (ctDNA) enables real-time molecular profiling, treatment monitoring, and early detection of resistance variants. We developed the PAN100 panel (Dxome), a hybridization capture panel targeting 101 genes, as a pan-cancer genotyping assay to detect...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Genotyping Techniques

Share to High-Throughput Nucleotide Sequencing

Share to Limit of Detection

Share to Liquid Biopsy

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 40888113
DOI: 10.3343/alm.2025.0171
PMCID: PMC12915377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and Performance Validation of a Comprehensive Liquid Biopsy Genotyping Panel for Pan-cancer Analysis.PMID 40888113Read ↗

Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.Semantic proximity Read ↗

A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)Semantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing-Based Comprehensive Tumor Profiling in Liquid Biopsy Samples.Semantic proximity Read ↗

Validation and Clinical Utility of a Pan-Cancer Circulating Tumor DNA Assay as a First-Approach Test.Semantic proximity Read ↗

Analytical Validation of a Pan-Cancer NGS Assay for In-House Liquid Biopsy Testing: An International Multicenter StudySemantic proximity Read ↗

Analytical validation and clinical utilization of K-4CARE<sup>TM</sup>: a comprehensive genomic profiling assay with personalized MRD detectionSemantic proximity Read ↗

Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice.Semantic proximity Read ↗

Clinical and Technical Validation of OncoIndx® Assay – A Comprehensive Genome Profiling Assay for Pan-Cancer InvestigationsSemantic proximity Read ↗

A clinician's handbook for using ctDNA throughout the patient journey.Semantic proximity Read ↗

Multimodal ctDNA profiling for cancer detection and monitoring in pan-cancer patients with advanced disease enrolled in the SHIVA02 trialSemantic proximity Read ↗

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.